摘要
目的 :探讨抗疱疹病毒药物黄芪A6 组分(A6)和无环鸟苷(ACV)联合抗 1型单纯疱疹病毒(HSV1 )的作用机制。方法 :利用竞争PCR检测A6 和ACV联合抗HSV1 的协同作用 ,并与细胞病变(CPE)抑制法进行比较。结果 :竞争PCR测定A6、ACV和A6+ACV对HSV1 的最小抑制浓度(MIC)分别为 1 88mg/ml、3 3 7μg/ml和 0 47mg/ml+ 0 84μg/ml;CPE抑制法测定A6、ACV和A6+ACV对HSV1 的MIC分别为 6 2 5mg/ml、5 0 μg/ml和 0 94mg/ml+ 1 2 5 μg/ml;联合抑制指数的分数(FICI)均小于 0 5 ;显示明显的联合协同抑制作用。结论 :定量PCR是筛选抗病毒药物的有效方法 ;结果还表明A6 和ACV对HSV1 的抑制作用主要表现在病毒增殖周期的复制阶段。
Objective: To evaluate the synergistic effect of Radix Astragali A 6 (A 6)and acyclovir (ACV) in antagonizing herpes simplex virus type Ⅰ (HSV 1). Methods: The synergistic effect was measured by competitive polymerase chain reaction (PCR) and compared with that measured by traditional cytopathic effect (CPE) inhibition method. Results: The minimum inhibition concentration of A 6, ACV and A 6+ACV measured by PCR was 1.88mg/ml, 3.37μg/ml and 0.47mg/ml+0.84μg/ml respectively, while measured by CPE, it was 6.25mg/ml, 50μg/ml and 0.94mg/ml+12.5μg/ml respectively. The fractional inhibitory combined indexes were all less than 0.5, which is an indication of obvious co synergistic effect. Conclusion: The quantitative PCR is an effective method of screening antiviral drugs. The inhibitory action of A 6 and ACV on HSV 1 revealed mainly at the replicative stage of viral proliferation cycle.
出处
《中国中西医结合杂志》
CAS
CSCD
北大核心
1998年第4期233-235,共3页
Chinese Journal of Integrated Traditional and Western Medicine
基金
贵州省科委基金资助!(93- 0 3)
关键词
定量
黄芪A6
无环鸟苷
1型
单纯疱疹病毒
PCR
quantitative polymerase chain reaction
Radix Astragali A 6
acyclovir
herpes simplex virus type Ⅰ
effective ingredient of drug